Per Fischer, D.Phil.
Dr. Fischer has 15 years experience from the biotech and pharmaceutical industry within product development and business development. He has founded and run several biotech companies, and has 5 years experience as a business and product development consultant within the sector. He holds a D.Phil. from University of Oxford and has 6 years of laboratory experience within immunology and infectious diseases.
Head of Manufacturing
Kim Ry Hejnaes, M.Sc.
Mr. Hejnaes has worked in the biopharmaceutical industry for more than 35 years as a protein chemistry principal scientist, project director, chief operating officer and chief executive officer hereof 20 years with Novo Nordisk and 5 years with CMC Biologics. Kim Hejnaes is the co- founder of L&K Biosciences, SMC Biotech, Hejnaes Consult, help4biotech and invest4biotech and serves as an adjunct professor in Biotechnology at University of Aalborg, Denmark. Since 1998, Kim Hejnaes has focused on outsourcing aspects of Chemistry, Manufacturing and Control (CMC) operations with involvement in a substantial number of international biotech projects over the years.
Head of Clinical Development
Michael Darsley D.Phil.
Dr. Mike Darsley has over 25 years experience in industrial Biotech in the USA, UK and Denmark in the fields of monoclonal antibodies and vaccines. He was VP bacterial vaccine research at Acambis UK, Chief Development Officer at ACE Biosciences and TD Vaccines in Denmark and has provided independent product development consultancy for 3 years to Pharma, Biotech and academic clients. He has a BA in Biochemistry and a D.Phil in molecular immunology from the University of Oxford and was a Fogarty International Postdoctoral Fellow at the National Cancer Institute, NIH, USA.
Chief Medical Officer
Geoff Kitson, M.D.
Geoff Kitson has over 27 years experience from the pharmaceutical industry, and a broad-based international perspective on drug development, from phase I to phase IV, experience of pre-clinical work, and regulatory requirements. He has been involved in the preparation of INDs, CTXs/CTAs, MAAs and other regulatory documents. He has experience in the development of individual clinical studies, clinical trial programmes, multinational clinical trials and developing clinical strategies. In the last few years he has taken 5 products including 5 vaccines through to first in man studies, and progressed products through to Phase II/III.
Scientific Advisor and Coordinator of NeoStrep EU Project
Bengt Johansson Lindbom, Ph.D.
Dr. Lindbom is an Associate Professor at the section for immunology, Lund University. His team studies the adaptive immune system, which underlies the development of protective immunological memory in response to infections or vaccination. Dr. Johansson Lindbom earned his Ph.D in immunotechnology in 2002. He then pursued post-doctoral work at the medical faculty at Lund University, studying mucosal immunology with particular focus on mucosal dendritic cells and the role they play in the orchestration of mucosal adaptive immune responses. In 2006, he was awarded a position as an Assistant Professor with the Swedish research council and has since then been the principal investigator for the research group Adaptive Immunity. Dr. Johansson-Lindbom is the author to a number of studies published in top-tiered international immunological journals, including the Journal of Experimental Medicine, the Journal of Immunology, Nature medicine and Immunity.
Board of Directors
Ingelise Saunders, Chairman
Ingelise has more than 35 years experience in the biotech and pharmaceutical industry. Until September 2013 she was CEO of the Swedish life science investment company SLS Invest AB. Prior to that she was CEO in three privately owned Danish Biotech companies, among these Action Pharma A/S, which was sold to Abbott in 2012. Prior to joining the biotech companies in 2004,she was Executive Director of Celltech Group plc in UK and CEO of Celltech Pharmaceuticals for 3 years until the acquisition of Celltech by UCB in 2004. Prior to joining Celltech, Ingelise Saunders held a series of senior executive positions during her 16 years at Novo Nordisk, and has also held senior commercial positions at Glaxo, Schering-Plough and Ferrosan. Ingelise Saunders is today a Director of the board of LEO Pharma A/S and Acesion Pharma.
Emmanuelle Coutanceau, PhD
Emmanuelle is Investment Director of Novo Seeds, the early stage investment arm of Novo A/S. Prior joining Novo Seeds, Emmanuelle was Investment Director at Auriga Partners, where she was in charge of seed stage investments for Auriga IV Bioseeds, a seed fund dedicated to projects related to infectiology and microbiology. Emmanuelle has more than 8 years of experience in venture capital investment and was part of Omnes capital (formerly Crédit Agricole Private Equity) from 2007 until 2014. She was in charge of the Seed Stage Investment Program and actively invested in Belgium and The Netherlands. Emmanuelle serves on the Board of Directors of Avilex Pharma, Minervax and Pcovery.
Sten is founding partner at Sunstone Capital A/S. He has more than 20 years experience as an international executive, entrepreneur and venture investor in biotech companies as well as pre-clinical and clinical CROs. Dr. Verland holds a M.Sc. in Biology and a Ph.D. in Immunology from the University of Copenhagen. After completing his doctorate, he held a number of academic positions in the field of biomedical research including the position of Assistant Professor in Immunology at the University of Copenhagen. In 1994, Dr. Verland headed a Management Buy-Out of a contract research organization (CRO) specializing in laboratory animal science and non-clinical development. After 4 years as a major shareholder, Dr. Verland merged the company with another CRO thus forming M&B A/S, which was subsequently acquired by Taconic, Inc., New York, in 2000. In 1998, Dr. Verland participated in the foundation of Synarc, Inc., San Francisco, and served for 4½ years as VP, General Manager Europe. During his tenure, Synarc developed from a small start-up clinical service provider into the world's largest central radiology service company dedicated exclusively to global clinical trials. From 2003 to 2007, Dr. Verland operated his own investment company where he co-founded or invested in 7 life science companies and served as non-executive director on 16 Boards.
Bent Østergaard is CEO of The Lauritzen Foundation and LF Investment the investment arm of Lauritzen Foundation. Bent joint The Lauritzen Group in 1970, and joint his current position in 1995. Bent has international management experience , board experience from international and listed companies and experience in finance.
Carsten Schou, PhD
Carsten is a General Partner at SEED Capital. He holds an MSc in biology and a PhD in Immunology from University of Copenhagen and Statens Seruminstitut. He has 11 years of operational experience in the pharmaceutical industry and has been Director of Research at ALK-Abelló A/S. He has held senior management positions in the biotechnology industry and has co-founded two biotech companies. He has been with Danske Private Equity prior to joining SEED Capital Denmark K/S. Carsten is currently on the Board of Directors of six small life science companies as well as the Biotechnology Research and Innovation Centre at the University of Copenhagen.
Annelie Sylven Troedsson
Annelie Sylvén Troedsson has since 1997 been part of developing the structures for collaboration between industry and universities in Sweden as head of the Legal division at Lund University, as well as supporting new companies based on research from the university. Since 2005 she has focused her activities on the latter as part of the team at LUIS, Lund University Innovation System. Before joining Lund University, she was Senior Legal Advisor at the Absolut Company, responsible for, i.a. IP-related matters.